Skip to main content

Aptose Biosciences Stock Forecast, Price & News

+0.06 (+1.23 %)
(As of 05/17/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume311,711 shs
Average Volume3.19 million shs
Market Capitalization$437.49 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive APTO News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Aptose Biosciences logo

About Aptose Biosciences

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.


See More Headlines

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:APTO
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Book Value$1.23 per share


Net Income$-26,280,000.00




Market Cap$437.49 million
Next Earnings Date8/3/2021 (Estimated)


Overall MarketRank

1.41 out of 5 stars

Medical Sector

684th out of 2,032 stocks

Biological Products, Except Diagnostic Industry

93rd out of 176 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions

Is Aptose Biosciences a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aptose Biosciences stock.
View analyst ratings for Aptose Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Aptose Biosciences?

Wall Street analysts have given Aptose Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aptose Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aptose Biosciences?

Aptose Biosciences saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 3,690,000 shares, a decline of 23.1% from the March 31st total of 4,800,000 shares. Based on an average trading volume of 4,190,000 shares, the days-to-cover ratio is currently 0.9 days. Currently, 4.5% of the company's stock are sold short.
View Aptose Biosciences' Short Interest

When is Aptose Biosciences' next earnings date?

Aptose Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Aptose Biosciences

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings data on Tuesday, May, 4th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.01.
View Aptose Biosciences' earnings history

How has Aptose Biosciences' stock been impacted by COVID-19?

Aptose Biosciences' stock was trading at $5.84 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APTO shares have decreased by 15.8% and is now trading at $4.92.
View which stocks have been most impacted by COVID-19

What price target have analysts set for APTO?

8 brokers have issued twelve-month price objectives for Aptose Biosciences' shares. Their forecasts range from $9.00 to $16.00. On average, they expect Aptose Biosciences' share price to reach $11.63 in the next year. This suggests a possible upside of 136.3% from the stock's current price.
View analysts' price targets for Aptose Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Aptose Biosciences' key executives?

Aptose Biosciences' management team includes the following people:
  • Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)
  • Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)
  • Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell, Chief Medical Officer (Age 73)
  • Mr. Peter Murray, Director of Clinical Devel.

What is William G. Rice, Ph.D.'s approval rating as Aptose Biosciences' CEO?

3 employees have rated Aptose Biosciences CEO William G. Rice, Ph.D. on William G. Rice, Ph.D. has an approval rating of 34% among Aptose Biosciences' employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Aptose Biosciences' key competitors?

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Who are Aptose Biosciences' major shareholders?

Aptose Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (8.70%), Woodline Partners LP (2.50%), Polar Capital Holdings Plc (2.06%), P.A.W. Capital Corp (0.78%), 683 Capital Management LLC (0.68%) and Carlson Capital L P (0.45%). Company insiders that own Aptose Biosciences stock include Gregory K Chow, Jotin Marango, Warren Whitehead and William G Rice.
View institutional ownership trends for Aptose Biosciences

Which institutional investors are selling Aptose Biosciences stock?

APTO stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Sanders Morris Harris LLC, Prosight Management LP, 683 Capital Management LLC, Bank of Montreal Can, P.A.W. Capital Corp, New York Life Investments Alternatives, and Renaissance Technologies LLC. Company insiders that have sold Aptose Biosciences company stock in the last year include Gregory K Chow, Jotin Marango, Warren Whitehead, and William G Rice.
View insider buying and selling activity for Aptose Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Aptose Biosciences stock?

APTO stock was bought by a variety of institutional investors in the last quarter, including Woodline Partners LP, Nantahala Capital Management LLC, Carlson Capital L P, Ikarian Capital LLC, Eversept Partners LP, Sigma Planning Corp, Polar Capital Holdings Plc, and Principal Street Partners LLC. Company insiders that have bought Aptose Biosciences stock in the last two years include Gregory K Chow, and William G Rice.
View insider buying and selling activity for Aptose Biosciences
or or view top insider-buying stocks.

How do I buy shares of Aptose Biosciences?

Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aptose Biosciences' stock price today?

One share of APTO stock can currently be purchased for approximately $4.92.

How much money does Aptose Biosciences make?

Aptose Biosciences has a market capitalization of $437.49 million. The biotechnology company earns $-26,280,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Aptose Biosciences have?

Aptose Biosciences employs 31 workers across the globe.

What is Aptose Biosciences' official website?

The official website for Aptose Biosciences is

Where are Aptose Biosciences' headquarters?

Aptose Biosciences is headquartered at 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The biotechnology company can be reached via phone at 858-926-2730 or via email at [email protected]

This page was last updated on 5/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.